Interest aplenty in Nuclidium’s solutions for radioisotope production

Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers.

The swift rise of Swiss biotech Nuclidium is evidence of this. The company is developing targeted copper-based radioligand therapeutics and companion diagnostics leveraging isotopes  61 Cu and  67 Cu, and is already entering the clinic.

Nuclidium was founded as a corporate spin-off in 2017, initially as a consultancy, before starting its own R&D activities a couple of years later. Leila Jaafar-Thiel, the chief executive and founder, who has been in the nuclear field since 2009, saw the opportunities in the field alongside co-founder Gustav von Schulthess, former director of Nuclear Medicine and co-director of Magnetic Resonance at University Hospital Zurich, and visiting professor of Radiology at Stanford University, USA.